Prometrium Regulatory Status: US, EU, Canada, and UK

What Is Prometrium and How Does It Work?

Prometrium is an oral capsule containing micronized progesterone suspended in peanut oil. Micronization reduces particle size to below 10 micrometers, increasing surface area and allowing meaningful gastrointestinal absorption that conventional progesterone powder cannot achieve. After a 200 mg oral dose in postmenopausal women, peak serum progesterone concentrations reach approximately 17 ng/mL at 3 hours, then decline with a terminal half-life of roughly 16 to 18 hours.

Receptor Binding and Endometrial Protection

Progesterone exerts its primary effect by binding the progesterone receptor (PR-A and PR-B isoforms) expressed in endometrial stromal and glandular cells. Receptor activation suppresses estrogen-receptor transcription, downregulates estrogen-driven cell proliferation, and shifts the endometrium from a proliferative to a secretory phenotype. This mechanism is the pharmacological basis for using progesterone alongside any systemic estrogen in women with an intact uterus: unopposed estrogen raises endometrial cancer risk by approximately 2- to 12-fold depending on duration of use, and progestogen co-administration reverses that risk [1].

How Micronized Progesterone Differs from Synthetic Progestins

Synthetic progestins such as medroxyprogesterone acetate (MPA) and norethindrone acetate share the core progestational mechanism but also bind androgen, glucocorticoid, and mineralocorticoid receptors to varying degrees. Micronized progesterone is structurally identical to the hormone produced by the corpus luteum and, at clinical doses, shows negligible androgenic or glucocorticoid receptor activity [2]. That selectivity underpins the lipid-profile advantage observed in the PEPI trial and the cardiovascular neutrality data reviewed in subsequent analyses.

Metabolite Activity

Oral micronized progesterone undergoes significant first-pass hepatic metabolism to allopregnanolone and pregnanolone, neuroactive metabolites that act as positive allosteric modulators of GABA-A receptors. These metabolites are responsible for the sedative effect that makes bedtime dosing standard practice across all four jurisdictions reviewed here. Vaginal progesterone formulations (gels, suppositories) largely bypass this first-pass conversion, which explains why vaginal routes produce negligible sedation despite adequate uterine tissue levels [3].

US Regulatory Status: FDA Approval and Prescribing Framework

The FDA first approved Prometrium (Solvay Pharmaceuticals, later AbbVie) in May 1998 under NDA 019781. The labeled indication covers two clinical scenarios: prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving 0.625 mg conjugated estrogens daily, and secondary amenorrhea in women 16 years and older [4].

Approved Doses and Regimens

The FDA label specifies 200 mg orally at bedtime for 12 consecutive days per 28-day cycle when used for endometrial protection in sequential HRT. For secondary amenorrhea the label directs 400 mg at bedtime for 10 days. Off-label continuous combined regimens at 100 mg nightly are widely used clinically; the Endocrine Society's 2022 menopause guidelines acknowledge continuous micronized progesterone 100 mg nightly as an evidence-based option for women preferring to avoid cyclical bleeding [5].

FDA Black-Box Warnings and Label Restrictions

The Prometrium label carries a class black-box warning shared with all estrogen-progestogen combination products. The warning references the Women's Health Initiative (WHI), which randomized 16,608 women and found the conjugated equine estrogen plus MPA arm (not the micronized progesterone arm) associated with increased breast cancer incidence, cardiovascular events, and stroke compared to placebo after a mean 5.6 years of follow-up [6]. Prometrium was not the progestogen used in WHI; however, FDA requires the class warning on all approved progestogens.

The label also explicitly contraindicates use in patients with known or suspected peanut allergy because the capsule shell contains peanut oil as the suspension vehicle.

Generic Availability in the US

The FDA has approved generic micronized progesterone 100 mg and 200 mg capsules from multiple manufacturers. As of mid-2025, at least six ANDA holders are listed in the FDA Orange Book as therapeutic equivalents (rated AB) to Prometrium [4]. This generic availability significantly affects cost and accessibility across US payers.

EU Regulatory Status: Utrogestan and the EMA Framework

Within the European Union, the brand name Prometrium is not the dominant commercial product. The equivalent preparation, Utrogestan (Besins Healthcare), holds national marketing authorizations in France, Germany, Belgium, Spain, Italy, and numerous other EU member states. France was the first country to approve micronized progesterone, doing so in 1980, nearly two decades before the FDA acted [7].

Authorized Indications Across Member States

EMA-coordinated mutual recognition and decentralized procedures have harmonized the core indication: endometrial protection in postmenopausal women receiving estrogen replacement therapy. Several member states additionally authorize Utrogestan for luteal-phase support in in vitro fertilization cycles and for threatened miscarriage, indications that exceed the scope of the US label. The 200 mg vaginal capsule formulation (used intravaginally off-label in the US) is authorized as a distinct product in several EU countries, reflecting the broader regulatory scope of the European framework [7].

EMA Pharmacovigilance and the ECHOS Study

A key piece of EU-specific evidence is the large observational ECHOS study (Etude Cohorte Hormones et Santé), which followed 80,377 French postmenopausal women. Transdermal estradiol combined with micronized progesterone was not associated with increased breast cancer risk compared with non-users (relative risk approximately 1.00), whereas women using synthetic progestins showed elevated risk [8]. The EMA's Committee for Medicinal Products for Human Use (CHMP) has referenced this data when reviewing periodic safety update reports for micronized progesterone products, though the agency has not amended the class-level breast cancer warning.

Formulation Differences in the EU

EU-authorized Utrogestan capsules are 100 mg and 200 mg, matching US strengths. The excipient profile, including sunflower oil in some national formulations rather than peanut oil, varies by country-specific manufacturing site and SmPC. Prescribers switching patients between jurisdictions should verify the specific SmPC for the dispensed product [7].

Canadian Regulatory Status: Health Canada Authorization

Health Canada authorized Prometrium under the brand name Prometrium (AbbVie Canada) for use in Canada. The Notice of Compliance was issued for the 100 mg capsule strength; the 200 mg strength received subsequent authorization. The Canadian product monograph specifies the indication as prevention of endometrial hyperplasia in postmenopausal women with an intact uterus who are receiving conjugated equine estrogens 0.625 mg daily [9].

Canadian Prescribing Dose

Health Canada's approved regimen mirrors the US label: 200 mg at bedtime for 12 days per 28-day cycle for sequential combined HRT. Canadian clinicians following the Menopause Society of Canada consensus statement also use continuous 100 mg nightly regimens, consistent with the broader North American clinical literature [9].

Off-Label Use in Assisted Reproduction

Canadian fertility specialists prescribe micronized progesterone for luteal-phase support in IVF cycles, a use that Health Canada has not formally approved but that is supported by evidence from randomized controlled trials. A 2021 Cochrane review (16 trials, N=2,556) found vaginal progesterone non-inferior to intramuscular progesterone for luteal support, and oral micronized progesterone showed lower live-birth rates than vaginal routes in head-to-head comparisons [10]. Canadian prescribers generally prefer vaginal formulations for ART accordingly.

Drug Identification Number and Generic Status

Prometrium 100 mg capsules carry DIN 02238146 and the 200 mg capsules carry DIN 02238147 in the Health Canada drug product database. Generic micronized progesterone from multiple manufacturers has received Notice of Compliance, reducing cost barriers for Canadian patients on provincial drug benefit plans.

UK Regulatory Status: MHRA Authorization and Utrogestan

The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) does not hold a marketing authorization for the Prometrium brand. Following Brexit, the UK operates its own authorization pathway independently from the EMA. The equivalent product, Utrogestan (Besins Healthcare UK), holds a UK Marketing Authorization (MA) under the MHRA [11].

MHRA-Authorized Indications

Utrogestan 100 mg capsules are authorized for endometrial protection in postmenopausal women receiving systemic estrogen therapy. Utrogestan 200 mg capsules hold authorization for the same HRT indication and for luteal-phase support in women undergoing medically assisted reproduction. The MHRA-approved Summary of Product Characteristics (SmPC) allows both oral and intravaginal routes for the 200 mg capsule, a dual-route authorization not present in the US label [11].

NICE Guidance and Clinical Practice

The National Institute for Health and Care Excellence (NICE) guideline NG23 on menopause (updated 2023) states: "Offer women who have a uterus and who are considering HRT a preparation that contains a progestogen to protect the endometrium." NICE specifically lists micronized progesterone as an option associated with a potentially more favorable safety profile compared to other progestogens based on observational data [12]. This NICE endorsement has substantially increased Utrogestan prescribing in the NHS since 2015.

UK Supply Shortages and Regulatory Response

The UK experienced significant Utrogestan supply shortages between 2019 and 2023, driven by demand increases following improved public awareness of menopause treatment options. The MHRA issued several temporary supply authorizations allowing unlicensed micronized progesterone products to be dispensed during shortage periods. By early 2024, manufacturers increased production capacity and shortages resolved in most regions, though individual pharmacies may still experience intermittent stock gaps [11].

Comparative Regulatory Summary Across Jurisdictions

The table below synthesizes the key regulatory parameters across the four jurisdictions for quick clinical reference.

| Parameter | US (FDA) | EU (EMA/National) | Canada (Health Canada) | UK (MHRA) | |---|---|---|---|---| | Brand name | Prometrium | Utrogestan | Prometrium | Utrogestan | | Manufacturer | AbbVie | Besins Healthcare | AbbVie Canada | Besins Healthcare UK | | Approval year | 1998 | 1980 (France) | Late 1990s | Post-Brexit MA maintained | | Strengths authorized | 100 mg, 200 mg | 100 mg, 200 mg | 100 mg, 200 mg | 100 mg, 200 mg | | Primary HRT indication | Yes | Yes | Yes | Yes | | Luteal support indication | No (off-label) | Yes (select states) | No (off-label) | Yes | | Dual oral/vaginal route | No | Yes (select states) | No | Yes | | Generic available | Yes (AB-rated) | Yes | Yes | Limited | | Peanut oil excipient | Yes | Varies by country | Yes | Sunflower oil (Utrogestan UK) |

The PEPI Trial: Core Evidence Underlying All Four Approvals

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, published in JAMA in 1995 (N=875), remains the most frequently cited randomized controlled trial supporting micronized progesterone use in HRT. PEPI randomized postmenopausal women to five arms: placebo, unopposed conjugated equine estrogens (CEE) 0.625 mg, CEE plus MPA cyclically, CEE plus MPA continuously, and CEE plus micronized progesterone 200 mg cyclically [13].

Endometrial Safety Results

Women in the unopposed CEE arm developed endometrial hyperplasia at a rate of 62% over three years, compared with under 1% in all progestogen-containing arms. Micronized progesterone provided complete endometrial protection equivalent to MPA at the doses tested [13]. This finding is the direct pharmacological rationale cited by FDA, EMA, Health Canada, and MHRA product monographs when they require co-administration of a progestogen with systemic estrogen.

Lipid Profile Advantage

PEPI also showed that CEE plus micronized progesterone raised HDL cholesterol by 4.1 mg/dL from baseline, compared with a rise of 1.6 mg/dL in the CEE plus MPA continuous arm (P<0.01). The difference reflected MPA's partial androgenic activity suppressing HDL, an effect absent with bioidentical progesterone [13]. Regulatory reviewers in the US and EU cited this lipid data when comparing progestogen options, though no jurisdiction has granted micronized progesterone a formal cardiovascular indication based on surrogate endpoints alone.

Prescribing Considerations Relevant to Regulatory Status

Contraindications Consistent Across All Jurisdictions

All four regulatory authorities list the following as absolute contraindications: known hypersensitivity to progesterone or any capsule component (including peanut oil where applicable), undiagnosed abnormal genital bleeding, known or suspected sex hormone-dependent malignancies, active thromboembolic disorder, and active or recent arterial thromboembolic disease. Liver impairment severe enough to impair drug metabolism is also a contraindication under all SmPCs reviewed [4] [9] [11].

Drug Interactions

CYP3A4 inducers (rifampicin, carbamazepine, phenytoin) accelerate progesterone metabolism and may reduce endometrial protection. CYP3A4 inhibitors (ketoconazole, clarithromycin) may raise progesterone levels and increase sedation. These interactions are noted in the FDA label and EU SmPCs and should inform co-prescribing decisions regardless of jurisdiction [2].

Monitoring Requirements

No jurisdiction mandates routine serum progesterone monitoring during HRT with oral micronized progesterone. Annual endometrial surveillance by transvaginal ultrasound is recommended if unexpected uterine bleeding occurs. The Endocrine Society's Clinical Practice Guideline on menopausal hormone therapy (2015, updated 2022) recommends endometrial biopsy for any postmenopausal bleeding occurring more than 12 months after the final menstrual period, regardless of progestogen type [5].

Mechanism Deep Dive: Why Bedtime Dosing Is Standard Practice

The 200 mg bedtime recommendation appears in every jurisdiction's prescribing information. The rationale is pharmacokinetic and pharmacodynamic. Peak allopregnanolone levels occur 1 to 3 hours after ingestion, coinciding with the onset of sleep in most patients who take the capsule at bedtime. Allopregnanolone enhances GABA-A receptor chloride conductance in a manner comparable to benzodiazepines at high concentrations, producing measurable sedation and anxiolysis [3].

Taking the capsule with food increases bioavailability by approximately 18%, per FDA pharmacokinetic data reviewed in the Prometrium label. Clinicians who find a patient reporting inadequate progesterone effect (breakthrough bleeding on sequential HRT) may consider advising consistent food co-administration before changing the dose, since the fasting-to-fed bioavailability difference is enough to affect endometrial exposure at the 200 mg level [4].